Venus Remedies Limited (VENUSREM) Price & Analysis

Compare

1 Followers

VENUSREM Stock Chart & Stats

₹782.25

-₹3.85(-1.26%)

At close: Jan 08 4:00 PM EST

₹782.25

-₹3.85(-1.26%)

Day’s Range― - ―

52-Week Range₹277.85 - ₹950.00

Previous CloseN/A

Volume28.34K

Average Volume (3M)2.33K

Market Cap

₹12.24B

Enterprise Value₹12.15B

Total Cash (Recent Filing)₹2.36B

Total Debt (Recent Filing)₹143.80M

Price to Earnings (P/E)10.0

Beta0.56

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)19.14

Shares Outstanding13,366,988

10 Day Avg. Volume2,529

30 Day Avg. Volume2,330

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)0.75

Price to Sales (P/S)0.65

P/FCF Ratio5.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Free Cash Flow StrengthSustained positive free cash flow and a strong operating cash flow-to-net-income ratio provide durable funding for capex, working capital, dividends or buybacks, and R&D. This cash conversion resilience reduces refinancing risk and supports strategic investments over the next 2–6 months and beyond.

Low Leverage / Strong Balance SheetA strong equity position and low financial leverage give the company flexibility to weather regulatory or market headwinds, pursue bolt-on M&A or expand capacity, and withstand reimbursement or pricing pressures common in pharmaceuticals without straining liquidity.

Improving Profitability And MarginsConsistent margin improvement and rising revenue reflect better cost controls, pricing power in hospital/critical-care segments, and operational efficiencies. Sustained margin expansion underpins durable earnings quality and enhances the company’s ability to reinvest for growth or return cash to shareholders.

Bears Say

Product/market ConcentrationHeavy concentration in hospital/critical-care and anti-infectives elevates exposure to hospital purchasing cycles, tender dynamics, antibiotic stewardship policies and regulatory scrutiny. Such concentration can amplify revenue volatility and limit resilience to structural shifts in hospital procurement.

Single-digit Revenue GrowthReported ~8% revenue growth is positive but modest; single-digit expansion may constrain scale benefits, slower market-share gains and the pace of reinvestment in new formulations or geographic registrations relative to faster-growing peers, affecting medium-term competitiveness.

Limited Disclosure On International Mix And Corporate CatalystsAbsent detail on geographic revenue split and a lack of recent notable corporate events reduce visibility on international diversification and near-term growth catalysts. This opacity complicates assessment of regulatory, market-entry, and execution risks for expanding export revenues.

Venus Remedies Limited News

Venus Remedies Alerts Shareholders to Special Window for Physical Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) just unveiled an update. Venus Remedies has notified stock exchanges that it...

8d ago

Venus Remedies Publishes Unaudited Q3 FY2025 Financial Results in Newspapers

An announcement from Venus Remedies Limited ( ($IN:VENUSREM) ) is now available. Venus Remedies Limited has notified the...

2M ago

Venus Remedies Closes Trading Window Ahead of December 2025 Results

Venus Remedies Limited ( ($IN:VENUSREM) ) has issued an update. Venus Remedies Limited has announced that, in accordance...

3M ago

Venus Remedies Opens Special Window for Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an update. Venus Remedies Limited has announced the opening of...

3M ago

Venus Remedies Completes AMR Licensing Milestones with Final Payment

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an update. Venus Remedies Limited has successfully completed all commercial...

3M ago

Venus Remedies Ensures Compliance with SEBI Regulations

An announcement from Venus Remedies Limited ( ($IN:VENUSREM) ) is now available. Venus Remedies Limited has announced compliance...

5M ago

Venus Remedies Aligns with SEBI’s Investment Ease Initiative

Venus Remedies Limited ( ($IN:VENUSREM) ) has provided an update. Venus Remedies Limited has announced the re-lodgement of...

7M ago

Venus Remedies Announces AGM Notice Publication

Venus Remedies Limited ( ($IN:VENUSREM) ) just unveiled an announcement. Venus Remedies Limited has announced a newspaper publication...

8M ago

VENUSREM FAQ

What was Venus Remedies Limited’s price range in the past 12 months?

Venus Remedies Limited lowest stock price was ₹277.85 and its highest was ₹950.00 in the past 12 months.

What is Venus Remedies Limited’s market cap?

Venus Remedies Limited’s market cap is ₹12.24B.

When is Venus Remedies Limited’s upcoming earnings report date?

Venus Remedies Limited’s upcoming earnings report date is Jun 03, 2026 which is in 77 days.

How were Venus Remedies Limited’s earnings last quarter?

Venus Remedies Limited released its earnings results on Jan 29, 2026. The company reported ₹19.137 earnings per share for the quarter, beating the consensus estimate of N/A by ₹19.137.

Is Venus Remedies Limited overvalued?

According to Wall Street analysts Venus Remedies Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Venus Remedies Limited pay dividends?

Venus Remedies Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Venus Remedies Limited dividends here

What is Venus Remedies Limited’s EPS estimate?

Venus Remedies Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Venus Remedies Limited have?

Venus Remedies Limited has 13,366,988 shares outstanding.

What happened to Venus Remedies Limited’s price movement after its last earnings report?

Venus Remedies Limited reported an EPS of ₹19.137 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.237%.

Which hedge fund is a major shareholder of Venus Remedies Limited?

Currently, no hedge funds are holding shares in IN:VENUSREM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Venus Remedies Limited

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin and wound care, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It also provides disinfectants; and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.